These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28471961)

  • 21. Arterial Obstruction on Computed Tomographic or Magnetic Resonance Angiography and Response to Intravenous Thrombolytics in Ischemic Stroke.
    Mair G; von Kummer R; Adami A; White PM; Adams ME; Yan B; Demchuk AM; Farrall AJ; Sellar RJ; Sakka E; Palmer J; Perry D; Lindley RI; Sandercock PA; Wardlaw JM;
    Stroke; 2017 Feb; 48(2):353-360. PubMed ID: 28008093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endovascular treatment or general treatment: how should acute ischemic stroke patients choose to benefit from them the most?: A systematic review and meta-analysis.
    Yang W; Zhang L; Yao Q; Chen W; Yang W; Zhang S; He L; Li H; Zhang Y
    Medicine (Baltimore); 2020 May; 99(20):e20187. PubMed ID: 32443338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review of outcome after ischemic stroke due to anterior circulation occlusion treated with intravenous, intra-arterial, or combined intravenous+intra-arterial thrombolysis.
    Mullen MT; Pisapia JM; Tilwa S; Messé SR; Stein SC
    Stroke; 2012 Sep; 43(9):2350-5. PubMed ID: 22811451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
    Lee SH; Kim BJ; Han MK; Park TH; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Nah HW; Lee J; Lee SJ; Ko Y; Kim JG; Park JM; Kang K; Cho YJ; Hong KS; Choi JC; Kim JT; Choi K; Kim DE; Ryu WS; Kim WJ; Shin DI; Yeo M; Lee J; Lee JS; Gorelick PB; Bae HJ
    Int J Stroke; 2016 Oct; 11(7):783-90. PubMed ID: 27312681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Intravenous thrombolysis in ischemic stroke: Therapeutic perspectives].
    Paris C; Derex L
    Rev Neurol (Paris); 2015 Dec; 171(12):866-75. PubMed ID: 26563662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial.
    Sherman DG; Atkinson RP; Chippendale T; Levin KA; Ng K; Futrell N; Hsu CY; Levy DE
    JAMA; 2000 May; 283(18):2395-403. PubMed ID: 10815082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Desmoteplase After Ischemic Stroke in Patients With Occlusion or High-Grade Stenosis in Major Cerebral Arteries.
    Lindsberg PJ; Caso V
    Stroke; 2016 Mar; 47(3):901-3. PubMed ID: 26846865
    [No Abstract]   [Full Text] [Related]  

  • 28. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Desmoteplase in the treatment of acute ischemic stroke.
    Dafer RM; Biller J
    Expert Rev Neurother; 2007 Apr; 7(4):333-7. PubMed ID: 17425487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Intravenous administration of a tissue plasminogen activator beyond 3 hours of the onset of acute ischemic stroke--MRI-based decision making].
    Kakuda W; Abo M
    Brain Nerve; 2008 Oct; 60(10):1173-80. PubMed ID: 18975605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endovascular Treatment with Stent-Retriever Devices for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.
    Bush CK; Kurimella D; Cross LJ; Conner KR; Martin-Schild S; He J; Li C; Chen J; Kelly T
    PLoS One; 2016; 11(1):e0147287. PubMed ID: 26807742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Thrombolytic Therapy for Stroke with Unknown Time of Onset: A Meta-Analysis of Observational Studies.
    Zhu RL; Xu J; Xie CJ; Hu Y; Wang K
    J Stroke Cerebrovasc Dis; 2020 May; 29(5):104742. PubMed ID: 32127258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.
    Anderson CS; Robinson T; Lindley RI; Arima H; Lavados PM; Lee TH; Broderick JP; Chen X; Chen G; Sharma VK; Kim JS; Thang NH; Cao Y; Parsons MW; Levi C; Huang Y; Olavarría VV; Demchuk AM; Bath PM; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Ricci S; Roffe C; Pandian J; Billot L; Woodward M; Li Q; Wang X; Wang J; Chalmers J;
    N Engl J Med; 2016 Jun; 374(24):2313-23. PubMed ID: 27161018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Repeated Thrombolysis with Alteplase in Early Recurrent Ischemic Stroke: A Systematic Review.
    Sarmiento RJC; Diestro JDB; Espiritu AI; San Jose MCZ
    J Stroke Cerebrovasc Dis; 2019 Oct; 28(10):104290. PubMed ID: 31371140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and effectiveness of endovascular treatment after 6 hours of symptom onset in patients with anterior circulation ischemic stroke: a matched case control study.
    Qureshi AI; Miley JT; Chaudhry SA; Semaan E; Rodriguez GJ; Suri MF; Adams HP
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1076-81. PubMed ID: 23099041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).
    Barreto AD; Ford GA; Shen L; Pedroza C; Tyson J; Cai C; Rahbar MH; Grotta JC;
    Stroke; 2017 Jun; 48(6):1608-1616. PubMed ID: 28507269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase.
    Piechowski-Jozwiak B; Abidi E; El Nekidy WS; Bogousslavsky J
    Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):165-176. PubMed ID: 34893967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Intravenous Low-Dose Alteplase in Relative Contraindication Patients with Acute Ischemic Stroke.
    Ohta T; Okada K; Fukuda M; Masahira N; Matsuoka T; Tsuno T; Takemura M
    J Stroke Cerebrovasc Dis; 2018 Jul; 27(7):1844-1851. PubMed ID: 29555402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mismatch-based delayed thrombolysis: a meta-analysis.
    Mishra NK; Albers GW; Davis SM; Donnan GA; Furlan AJ; Hacke W; Lees KR
    Stroke; 2010 Jan; 41(1):e25-33. PubMed ID: 19926836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.